KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bristol Myers Squibb (BMY) Asset Writedowns and Impairment (2016 - 2025)

Bristol Myers Squibb (BMY) has disclosed Asset Writedowns and Impairment for 16 consecutive years, with $584.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Asset Writedowns and Impairment fell 70.1% to $584.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $2.9 billion, a 3.07% decrease, with the full-year FY2025 number at $1.1 billion, down 62.94% from a year prior.
  • Asset Writedowns and Impairment was $584.0 million for Q4 2025 at Bristol Myers Squibb, up from $196.0 million in the prior quarter.
  • In the past five years, Asset Writedowns and Impairment ranged from a high of $2.0 billion in Q4 2024 to a low of $1.0 million in Q1 2024.
  • A 5-year average of $299.1 million and a median of $100.0 million in 2022 define the central range for Asset Writedowns and Impairment.
  • Peak YoY movement for Asset Writedowns and Impairment: crashed 98.6% in 2021, then soared 6634.48% in 2024.
  • Bristol Myers Squibb's Asset Writedowns and Impairment stood at $15.0 million in 2021, then soared by 133.33% to $35.0 million in 2022, then dropped by 17.14% to $29.0 million in 2023, then skyrocketed by 6634.48% to $2.0 billion in 2024, then tumbled by 70.1% to $584.0 million in 2025.
  • Per Business Quant, the three most recent readings for BMY's Asset Writedowns and Impairment are $584.0 million (Q4 2025), $196.0 million (Q3 2025), and $2.0 billion (Q4 2024).